Veracyte

$46.53 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Veracyte

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Stock Analysis

last close $46.45
1-mo return -3.6%
3-mo return 21%
avg daily vol. 368.11T
52-week high 86.03
52-week low 32.87
market cap. $3.2B
forward pe -
annual div. -
roe -10.5%
ltg forecast -
dividend yield -
annual rev. $157M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe